Latest news with #Rytelo
Business Upturn
2 days ago
- Business
- Business Upturn
Geron Corporation Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Geron Corporation ('Geron' or 'the Company') (NASDAQ: GERN) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Geron investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Advertisement Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. The Complaint alleges that, throughout the Class Period, Defendants provided investors with material information regarding the anticipated launch and growth potential of Rytelo (imetelstat). Specifically, the Complaint asserts that Defendants repeatedly expressed confidence in Geron's ability to capitalize on the purportedly significant unmet medical need for the drug and to execute its commercial plan targeting first-line ESA-ineligible patients, while downplaying or minimizing risks associated with the weekly monitoring requirements for Rytelo, as well as the potential impacts of seasonality and competition on the drug's sales. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq. Admitted CA, NY and TX Bars [email protected] 310-692-8883 Attorney Advertising Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Upturn
13-05-2025
- Business
- Business Upturn
Geron Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. May 12 2025 Deadline to file Lead Plaintiff Motion.
LOS ANGELES, May 12, 2025 (GLOBE NEWSWIRE) — Investors can contact the law firm at no cost to learn more about recovering their losses The Portnoy Law Firm advises Geron Corporation ('Geron' or the 'Company') (NASDAQ: GERN) investors of a class action representing investors that bought securities between February 28, 2024 and February 25, 2025, inclusive (the 'Class Period'). Acadia Healthcare investors have until May 12 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. The Geron class action lawsuit alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (i) defendants falsely suggested they possessed reliable information regarding Geron's projected revenue outlook and anticipated growth, while downplaying risks related to seasonality and broader macroeconomic conditions; (ii) in reality, Geron's optimistic portrayals of Rytelo's launch success and growth potential were overstated, as seasonality, existing competition, and the ongoing monitoring requirements had a far greater impact on patient uptake than defendants had indicated; and (iii) Rytelo lacked sufficient market awareness to achieve meaningful penetration, preventing Geron from capitalizing on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside academic medical settings. The lawsuit further claims that, on February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal year 2024, revealing that Rytelo's growth had stagnated over the prior months. The company attributed the slowed growth to seasonality, competitive pressures, limited awareness of Rytelo, and the burden associated with the drug's required monitoring. Following this announcement, Geron's stock price fell by more than 32%, according to the complaint. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, CA and NY Bar [email protected] 310-692-8883
Business Wire
12-05-2025
- Business
- Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Geron Corporation ('Geron' or the 'Company') (NASDAQ: GERN) and reminds investors of the May 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi reminds investors of the May 12, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Share Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements. Defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug's sales. On February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that Rytelo's growth had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. Following this news, the price of Geron's common stock declined dramatically. From a closing market price of $2.37 per share on February 25, 2025, Geron's stock price fell to $1.61 per share on February 26, 2025, a decline of about 32.07% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Geron's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Geron class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Yahoo
09-05-2025
- Business
- Yahoo
Why Geron Stock Crept Higher Today
The company now has a reliable revenue stream thanks to its first commercialized drug. Nevertheless, analysts were expecting higher revenue in its first quarter. 10 stocks we like better than Geron › Shares of commercial-stage biotech Geron (NASDAQ: GERN) couldn't quite surmount the hump of Hump Day. After the company released its latest set of quarterly figures, its stock price wobbled as investors determined how best to digest the results. Finally, the stock closed on a downbeat note, booking a 0.8% loss on the day and comparing unfavorably to the slight (0.4%) gain of the S&P 500 index. Geron unveiled its first-quarter numbers well before market open, showing that the oncology-focused biotech earned $39.6 million during the period. Nearly all of this was derived from sales of Rytelo, the company's cancer drug that won Food and Drug Administration (FDA) approval in June 2024. Year-over-year comparisons are therefore meaningless, as the company had no product revenue in the first quarter of 2024. On the bottom line, now that Geron has a revenue stream, thanks to Rytelo, the company's net loss narrowed to $19.8 million ($0.03 per share) from the year-ago quarter's $55.4 million. Analysts tracking the company's fortunes were clearly expecting notably higher take-up of the drug, however. On average, they were modeling just under $50.5 million for total revenue. By contrast, their estimate for net loss was in line at $0.03. Geron waxed bullish on Rytelo's future. In the earnings release, Geron quoted interim president and CEO Dawn Bir saying, "We have received positive feedback from clinicians who have utilized Rytelo, supporting its strong therapeutic profile. We've identified specific opportunities and are making focused investments that we believe will strengthen the U.S. commercial trajectory." Geron also maintained its existing guidance for operating expenses. It estimates that these will come in at $270 million to $285 million for the entirety of this year. It added that its current level of cash, equivalents, and marketable securities will suffice "to fund projected operating requirements for the foreseeable future." It did not get more specific. Before you buy stock in Geron, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Geron wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $613,546!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $695,897!* Now, it's worth noting Stock Advisor's total average return is 893% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Geron Stock Crept Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
09-05-2025
- Business
- Business Wire
GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Geron Corporation ('Geron' or 'the Company') (NASDAQ: GERN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Geron gave investors the false impression that it had reliable information about its projected revenue outlook and anticipated growth. The Company's optimistic reports of Rytelo's launch and potential growth were far too optimistic. The Company failed to inform investors that Rytelo lacked necessary patient awareness for the Company to capitalize on what it had claimed was a significant unmet need for the drug. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Geron, investors suffered damages. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
